Am I eligible for this trial based on my current health and treatment history?

This is a question you may want to discuss with your doctor regarding the Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) clinical trial (NCT06796998). Contact the study team or your healthcare provider for specific answers.

What are the potential side effects of Epcoritamab?

This is a question you may want to discuss with your doctor regarding the Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) clinical trial (NCT06796998). Contact the study team or your healthcare provider for specific answers.

How does this treatment compare to other options available for my condition?

This is a question you may want to discuss with your doctor regarding the Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) clinical trial (NCT06796998). Contact the study team or your healthcare provider for specific answers.

What will the treatment schedule look like, and how often will I need to visit the clinic?

This is a question you may want to discuss with your doctor regarding the Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) clinical trial (NCT06796998). Contact the study team or your healthcare provider for specific answers.

Are there any specific tests or procedures I will need to undergo during the trial?

This is a question you may want to discuss with your doctor regarding the Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) clinical trial (NCT06796998). Contact the study team or your healthcare provider for specific answers.

What support will be available to me during the trial?

This is a question you may want to discuss with your doctor regarding the Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) clinical trial (NCT06796998). Contact the study team or your healthcare provider for specific answers.

Finding studies

Back

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

NCT067969981 siteClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Clareo Health | Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)